VERONA PHARMA PLC's ticker is VRNA and the CUSIP is 925050106. A total of 89 filers reported holding VERONA PHARMA PLC in Q4 2022. The put-call ratio across all filers is 0.23 and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $65,317,311 | -30.2% | 4,007,197 | -18.2% | 2.18% | -19.6% |
| Q2 2023 | $93,630,032 | +70.6% | 4,897,116 | +79.1% | 2.71% | +67.2% |
| Q1 2023 | $54,894,503 | -57.0% | 2,733,790 | -44.0% | 1.62% | -54.7% |
| Q4 2022 | $127,533,187 | +147.2% | 4,880,719 | -3.3% | 3.58% | +139.2% |
| Q3 2022 | $51,583,000 | +322.3% | 5,047,264 | +73.1% | 1.50% | +290.9% |
| Q2 2022 | $12,214,000 | -19.6% | 2,915,146 | -4.2% | 0.38% | +26.0% |
| Q1 2022 | $15,191,000 | -60.6% | 3,044,303 | -46.9% | 0.30% | +2.4% |
| Q4 2021 | $38,540,000 | +143.4% | 5,735,020 | +98.5% | 0.30% | +29.1% |
| Q3 2021 | $15,831,000 | -58.1% | 2,888,889 | -50.0% | 0.23% | -6.1% |
| Q2 2021 | $37,786,000 | +56.5% | 5,777,778 | +100.0% | 0.24% | -19.7% |
| Q1 2021 | $24,151,000 | +19.4% | 2,888,889 | 0.0% | 0.30% | +40.6% |
| Q4 2020 | $20,222,000 | +12.2% | 2,888,889 | 0.0% | 0.22% | -17.5% |
| Q3 2020 | $18,027,000 | +5772.0% | 2,888,889 | +12839.0% | 0.26% | +3187.5% |
| Q2 2018 | $307,000 | -72.7% | 22,327 | -60.2% | 0.01% | -74.2% |
| Q1 2018 | $1,123,000 | -52.9% | 56,168 | -71.9% | 0.03% | -60.8% |
| Q4 2017 | $2,384,000 | -61.2% | 200,000 | -50.0% | 0.08% | -32.5% |
| Q3 2017 | $6,140,000 | +163.4% | 400,000 | +100.0% | 0.12% | 0.0% |
| Q2 2017 | $2,331,000 | – | 200,000 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,332,485 | $34,817,833 | 22.99% |
| Abingworth LLP | 2,457,500 | $64,214,475 | 20.92% |
| Fairmount Funds Management LLC | 2,875,526 | $75,137,494 | 11.92% |
| Octagon Capital Advisors LP | 2,468,000 | $64,488,840 | 10.04% |
| NEA Management Company, LLC | 5,584,753 | $145,929,596 | 8.20% |
| Knoll Capital Management, LLC | 95,391 | $2,492,567 | 5.62% |
| Frazier Life Sciences Management, L.P. | 2,815,720 | $73,574,764 | 4.57% |
| Resolute Capital Asset Partners LLC | 185,992 | $4,860 | 4.34% |
| Caligan Partners LP | 183,064 | $4,783,462 | 3.98% |
| Samsara BioCapital, LLC | 695,001 | $18,160,376 | 3.91% |